1 May 2015
A new study has shown promising results for patients with hepatitis C who are waiting for a liver transplant.
"The problem for these patients is that unless the hepatitis C is cured, the virus continues circulating in their blood infecting the new liver, usually within a few months of transplant. One-third of them have cirrhosis again within five years," explained Dr Fred Poordad, clinical professor of medicine and chief of hepatology at the University of Texas Health Science Center at San Antonio.
Presented at the International Liver CongressTM of the European Association for the Study of the Liver (EASL), the study evaluated a 12-week course of daclatasvir - the new drug being evaluated - combined with sofosbuvir and ribavirin for patients with chronic hepatitis C.
It found an overall cure rate of 94 per cent of patients waiting for patients with a liver transplant and returning hepatitis C, and 83 per cent for patients with advanced cirrhosis. The study's primary endpoints were also achieved, with 95 per cent of post-transplant genotype 1 patients and 82 per cent of genotype 1 patients with advanced cirrhosis being cured 12 weeks after treatment.
Posted by Phillip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.